Advertisements

Dormex (Zopiclone)

Quick links to important sections

Dormex (Zopiclone)

Advertisements
Advertisements

Method of action: Hypnotic

Treatment option: Insomnia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Dormex (Zopiclone)

What is Dormex (Zopiclone)?

Dormex is a brand-name pharmaceutical product containing the active ingredient zopiclone. It belongs to a class of medications known as Z-drugs, which are non-benzodiazepine hypnotics. While they differ in chemical structure from traditional benzodiazepines, they produce similar effects on the central nervous system to promote sleep.

Mechanism of Action

Zopiclone works by modulating the gamma-aminobutyric acid (GABA) receptors in the brain. GABA is a neurotransmitter responsible for reducing neuronal excitability throughout the nervous system. By enhancing the activity of these receptors, Dormex helps to:

  • Decrease the time it takes to fall asleep (sleep latency).
  • Reduce the frequency of nighttime awakenings.
  • Increase the total duration of sleep.

Clinical Application

Dormex is primarily utilized for the short-term management of various forms of insomnia, including:

  • Transient Insomnia: Short-term sleep disturbances often caused by temporary changes in environment or schedule.
  • Short-term Insomnia: Difficulty sleeping related to acute stress or situational factors.
  • Chronic Insomnia: Long-term sleep issues, though the use of zopiclone in these cases is typically limited to brief periods to avoid the development of tolerance.

Pharmacological Properties

As a sedative-hypnotic, zopiclone is characterized by its rapid absorption into the bloodstream, usually leading to the onset of sleep shortly after administration. It is metabolized by the liver and excreted through the kidneys. Because of its specific half-life, it is designed to assist with sleep maintenance while minimizing the risk of significant morning drowsiness when used as directed.

Advertisements

What side effects are possible with Dormex (Zopiclone)?

Zopiclone’s safety profile is defined by officially documented adverse reactions classified by frequency and by the physiological system affected. The most frequently observed reactions are related to the central nervous system (CNS) and taste perception.

Frequency-Classified Adverse Reactions

Adverse events are categorized according to regulatory standards (e.g., EMA/FDA):

Classification Examples of Reactions
Common Dysgeusia (bitter taste), Somnolence (drowsiness), Dizziness, Headache, Dry mouth, Fatigue.
Uncommon Nausea, Vomiting, Agitation, Nightmares, Rash, Pruritus.
Rare Anterograde Amnesia, Confusion, Hallucinations, Aggression, Dependence, Dyspnea.

Reactions categorized as not known (frequency cannot be estimated from available data) include complex sleep behaviors, such as sleep-driving, and the post-cessation emergence of a withdrawal syndrome or rebound insomnia.

Serious Safety Considerations

Regulatory documents highlight several serious adverse reactions, including the potential for complex sleep behaviors (performing activities while not fully awake) and the risk of anterograde amnesia, which is impaired memory for events that occur after the drug is taken. The risk of developing physical and psychological dependence increases significantly with higher doses and use beyond the recommended short-term duration.

Population and Constraint Notes

The medication is subject to specific safety restrictions. It is contraindicated in patients with severe respiratory insufficiency, severe hepatic insufficiency, Myasthenia Gravis, and Sleep Apnoea Syndrome. Official labeling notes that older adults face an increased risk of falls and fractures due to the drug’s effects.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the Zopiclone overdose profile by the primary risk of Central Nervous System (CNS) depression, which affects consciousness and vital functions.

Category Official Regulatory Statements
Documented overdose presentations Overdose presentations are characterized by somnolence, a confusional state, ataxia (loss of coordination), and muscular hypotonia (floppy muscles).
Physiological systems affected The CNS is the primary system affected. Respiratory function can be severely impaired, and the Cardiovascular system may show effects like hypotension (low blood pressure).
Dose-related or exposure-related factors The risk of coma and death is profoundly increased when Zopiclone is combined with other CNS depressants, particularly opioids or alcohol. Regulators advise prescribing the smallest feasible quantity for patients with suicidal tendencies.
Emergency-response statements Immediate medical attention must be sought if overdose is suspected. Treatment is symptomatic and supportive, and medical professionals may consider measures such as activated charcoal or gastric lavage.
When immediate medical help is required Urgent medical help is explicitly required for signs of severe effects, including difficulty breathing or swallowing, or swelling of the face, tongue, or throat (angioedema).

Official Overdose Statements

  • Overdose presents with signs of CNS depression, progressing from confusion to severe respiratory compromise.
  • The most severe outcomes are respiratory depression, coma, and death.
  • Immediate medical attention must be sought if overdose is suspected, especially with breathing difficulties.
  • Treatment is symptomatic and supportive, though flumazenil has been reported as an agent used to reverse effects in clinical contexts.

The official profile strictly mandates when emergency medical help must be sought, explicitly listing signs like breathing difficulties as triggers for immediate action. Specific regulatory warnings emphasize that intentional overdose risk must be mitigated by careful prescribing, and severity is amplified by co-ingestion with other depressants.

Advertisements

Therapeutic Uses of Dormex (Zopiclone)

What Dormex (Zopiclone) treats: main uses and benefits

Zopiclone, often sold under the brand name Dormex, is primarily designated for the short-term management of insomnia in adults. The medication is considered when sleep disturbance significantly impacts a person's daily functioning.

The primary purpose of treatment is to address common insomnia symptoms, such as difficulty initiating sleep, frequent nighttime awakenings, and early morning waking. These indications cover various clinical scenarios, including when insomnia is transient or short-term. The intended benefit is to support improvement in the overall quality and duration of sleep. Zopiclone is a treatment option for sleeping problems (insomnia), offering support when sleep deprivation is causing distress.


Quick Fact: Supports short-term management of insomnia symptoms


Advertisements

Eligibility and Restrictions for Use

Zopiclone (Dormex) is officially designated for use only by adult patients (aged 18 and older). Regulatory authorities strictly define patient eligibility through absolute prohibitions and conditional limitations.

Absolute Contraindications

Use of Zopiclone is contraindicated in patients with:

  • Severe Organ Compromise: Severe hepatic insufficiency, severe respiratory insufficiency, or severe sleep apnoea syndrome.
  • Physical Conditions: Myasthenia Gravis (muscle weakness).
  • Prior History: Hypersensitivity to zopiclone or a history of complex sleep behaviors (e.g., sleep-driving) after taking the medicine.

Age and Physiological Restrictions

Population Eligibility Status
Pediatric Patients (Under 18) Contraindicated. Safety and efficacy are not established in this age group.
Elderly Patients (65 and older) Restricted use. Treatment must be initiated with a lower dose due to increased sensitivity and risk of adverse effects.
Pregnancy and Lactation Not recommended or Avoided. The drug is excreted into breast milk, and use during pregnancy has insufficient safety data.
Impaired Organ Function Use in renal impairment or non-severe hepatic impairment is restricted, requiring initiation at a lower dose.
Comorbidities Use requires extreme caution in patients with a history of alcohol or drug abuse due to the increased risk of dependence.
Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Dormex (Zopiclone) is defined by its metabolic pathway and its central nervous system (CNS) activity, establishing clear co-administration constraints documented in regulatory labeling.

Official Interaction Statements

Zopiclone co-administration is classified based on two main mechanisms:

  • Pharmacodynamic Enhancement: The combination of Zopiclone with alcohol or other CNS depressants (e.g., Opioids, Antipsychotics, Antidepressants, Anxiolytics) leads to an additive pharmacodynamic enhancement of the central sedative effect. Regulatory information notes that co-administration with Opioids is reserved for situations where alternatives are inadequate due to the documented risk of profound sedation and respiratory depression. Alcohol consumption must be avoided.
  • Pharmacokinetic Modulation: Zopiclone's systemic exposure is altered by substances affecting the CYP3A4 enzyme. Strong CYP3A4 inhibitors (including Erythromycin, Ketoconazole, and Ritonavir) increase Zopiclone exposure by inhibiting its metabolism. Conversely, strong CYP3A4 inducers (such as Rifampicin, Phenytoin, and the herbal product St. John's Wort) decrease Zopiclone exposure by accelerating its metabolism.

Administration and Population Constraints

To address the risk of next-day impairment, the regulatory label mandates a minimum interval of 12 hours between Zopiclone administration and the performance of activities requiring full mental alertness, such as driving or operating machinery. Population-specific notes require caution in elderly patients and those with hepatic impairment, as reduced clearance may increase the severity of these documented interactions.

Advertisements

Mechanism of Action

Central Nervous System Inhibition

Dormex (Zopiclone) functions as a positive allosteric modulator of the gamma-aminobutyric acid ( GABAA) receptor complex in the central nervous system (CNS). This binding action enhances the effect of GABA, the primary inhibitory neurotransmitter in the brain. The resulting physiological consequence is increased neuronal inhibition, leading to widespread CNS depression, evidenced by reduced neuronal excitability across various brain regions.


Potentiation of Chloride Ion Flux

The GABAA receptor is a ligand-gated chloride ion channel. Zopiclone's interaction with the receptor increases the frequency of the channel's opening. This allows a greater influx of chloride ions ( Cl^-) into the neuron, which hyperpolarizes the cell membrane. This hyperpolarization makes the neuron less excitable and reduces its ability to fire an action potential, thereby facilitating the physiological conditions for reduced wakefulness.


Receptor Subunit Specificity

As a non-benzodiazepine agent of the cyclopyrrolone class, Zopiclone preferentially binds with high affinity to the alpha1 subunit of the GABAA receptor complex, the subtype primarily linked to modulation of sleep-wake cycles. This specific modulation helps to constrain the propagation of excitatory signals within relevant neural circuits, shaping the agent's characteristic profile of action.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Zopiclone is an orally administered medication that is formulated as a film-coated tablet. The fundamental principle of its administration is a strict once-daily, single-dose regimen taken immediately before bedtime. The tablet must be swallowed whole with water, and the dose should not be re-administered later in the night.

Dosage and Duration Protocol

The standard adult dose is generally 7.5 mg per night, which is also the established maximum recommended daily dose. A crucial procedural condition for administration is the necessity for the patient to be able to commit to a full seven to eight hours of uninterrupted rest following intake. The total treatment course is designated for short-term use only and is intended to not exceed four weeks, including any necessary period for dose reduction.

Population-Specific Use

Lower starting doses are indicated for specific populations. For older adults (geriatric patients) and patients with hepatic or renal impairment, the recommended initial nightly dose is 3.75 mg. This lower dose applies to those with chronic respiratory insufficiency as well. Zopiclone is generally not recommended for use in individuals under 18 years of age due to a lack of established safety and efficacy in the pediatric population.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dormex (Zopiclone)

Evidence for use in Short-Term Insomnia

Research examined Dormex (Zopiclone) within the context of adults experiencing short-term sleep difficulties. These studies were mostly conducted as Randomized Controlled Trials (RCTs), a research type often used in evidence gathering. The trials were relevant in examining conditions associated with acute or disruptive episodes, such as difficulty falling asleep, staying asleep, or waking up too early.

Studies monitored outcomes reflecting daily functioning or activity level, specifically how sleep patterns evolved in the observed populations during the short study period. Researchers measured specific endpoints, such as the time taken for participants to fall asleep and the total duration of sleep achieved. Findings describe patterns observed in the studies, where measured changes were reported across different groups during the defined time intervals. Research provides context but not individual predictions.

Long-Term Studies and Extended Follow-up

The main body of research examining Dormex (Zopiclone) was relevant in trials assessing short-term symptom patterns, typically for periods lasting only a few weeks. The evidence for continuous use beyond this period is limited.

When studies explored symptom patterns over defined time intervals longer than a few weeks, the available evidence is limited and was observed in different types of research, such as observational settings. Studies report how symptoms evolved in the observed populations, but long-term effects are not fully established regarding the sustained effects of the drug. Certainty remains low regarding the full profile of use over months or years.

What is Still Uncertain about Dormex (Zopiclone) Research

One of the primary limitations is that follow-up durations were limited in many of the initial trials. There is limited information for long-term outcomes regarding the development of reduced responsiveness over time. Furthermore, comparative evidence is lacking in direct head-to-head trials against many other available options for short-term sleep difficulties. The results apply only to the populations studied in the trials, and research does not determine whether an individual outside of those precise conditions will respond similarly.

Key Studies & References

  1. Long-term sedative use among community-dwelling adults: a population-based analysis
  2. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (NICE Technology Appraisal TA77)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Dormex (Zopiclone) (FAQ)


Q: Can Dormex cause a weird taste in my mouth, and is that common?

Official safety documents describe Dysgeusia, often referred to as a bitter or metallic taste in the mouth, as a very common adverse reaction to Dormex. This means it is among the most frequently observed effects reported in studies.


Q: Can taking Dormex cause me to feel groggy or 'hungover' the next day?

Official information lists 'Somnolence' (drowsiness), dizziness, and fatigue as common side effects. Regulatory warnings acknowledge the risk of next-day impairment, which can manifest as feeling groggy or less alert.


Q: Can Dormex cause changes in mood or make me feel irritable?

Mood and behavioral changes have been reported with this medication. Official documents classify agitation as an uncommon side effect and aggression as rare. Warnings also indicate that worsening of existing depression or the emergence of suicidal thoughts may occur.


Q: Can women who are pregnant or breastfeeding use Dormex?

Zopiclone is generally not recommended for use during pregnancy because there is insufficient data to establish its safety. Official documents also confirm that the medicine is excreted into breast milk.


Q: Is Dormex the same type of medicine as Ambien (Zolpidem)?

Official regulatory documents classify Dormex (Zopiclone) as a non-benzodiazepine sedative-hypnotic, also commonly called a 'Z-drug.' While it is similar to Ambien (Zolpidem) in its functional effect on the brain’s GABA system, they belong to different chemical groups.


Q: How long does it typically take for Dormex to start making you feel sleepy?

The onset of action is reported to be rapid, often within 30 minutes. For this reason, official documentation advises that the tablet be taken immediately before going to bed.


Q: What is the average duration of the effects of Dormex?

The time it takes for half of the drug to be eliminated from the body (the half-life) is generally reported to be about 4 to 6 hours. The total duration of effect is generally consistent with the official requirement for a patient to commit to a full 7 to 8 hours of uninterrupted rest following intake.


Q: Do you get withdrawal symptoms if you stop taking Dormex after using it for a short time?

Regulatory documents state that withdrawal symptoms, which can include rebound insomnia (the return of severe sleep issues) and anxiety, may occur when the medicine is stopped. This risk is primarily linked to high doses and extended use, but abrupt discontinuation should be approached with caution even after short-term use.


Q: Is there a risk of becoming dependent on Dormex?

Yes, official warnings address the potential for both physical and psychological dependence with this medication. Regulatory documents caution that the risk of dependence increases significantly when the medicine is used for longer than the recommended short-term duration or at higher doses.


Q: What are the possible long-term effects of taking Dormex?

Dormex is officially approved for short-term symptomatic treatment only, typically not to exceed four weeks. Regulatory overviews note that the evidence for continuous use over longer periods is limited, meaning the full safety profile for long-term effects is not fully established.


Q: Can Dormex affect my ability to drive the morning after taking it?

Yes, official warnings clearly state that Dormex can cause next-day impairment, including drowsiness and reduced alertness. Official labels describe a required minimum interval of 12 hours between taking the medicine and operating machinery or driving.


Q: Is it okay to take Dormex if I have chronic pain?

Official warnings note that Zopiclone’s sedative effects can be enhanced when it is combined with other Central Nervous System (CNS) depressants, such as certain opioid pain medications. The official documents do not provide specific guidance on general chronic pain conditions that are not managed with CNS depressants.


Q: Is it safe to drink coffee or caffeine while taking Dormex?

Official interaction lists focus on CNS depressants, such as alcohol, and do not specifically name caffeine. However, caffeine is a stimulant and could potentially counteract the medication's intended sleep-inducing effect.


Q: Are there specific foods that should be avoided when taking Dormex?

Official documents generally state that the medicine can be taken with or without food. Regulatory warnings about drug metabolism may suggest avoiding grapefruit juice, as it is known to inhibit the enzyme that breaks down Zopiclone, potentially increasing the amount of medicine in the body.


Q: What are the signs that someone might be having an allergic reaction to Dormex?

Serious side effects, including signs of a serious allergic reaction, have been reported in official documents. These signs can include swelling of the face, lips, mouth, or throat, which can cause difficulty breathing or swallowing, along with severe itching or a rash.


Q: Is it common to have unusual dreams or nightmares while taking Dormex?

Nightmares are listed in official safety documents as an uncommon adverse reaction, meaning it affects a small percentage of users. The term 'unusual dreams' is generally covered under similar categories of sleep disturbance.


Q: What research is available on using Dormex for treating jet lag?

Regulatory documents state that Dormex (Zopiclone) is officially approved for the short-term symptomatic treatment of insomnia. The drug is not indicated or approved by regulatory bodies for the specific treatment of jet lag.


Q: Does Dormex lose its effectiveness over time if used regularly?

Official documentation acknowledges that a degree of tolerance may develop after repeated use for a few weeks. Tolerance means the hypnotic effects may become reduced, and this is a key reason for the official restriction on short-term use.


Q: How quickly does Dormex leave the body after you stop taking it?

The elimination half-life, which measures the rate at which the body clears the drug, is approximately 4 to 6 hours in most adults. It takes several half-lives for the medicine to be substantially cleared from the bloodstream.


Q: Is Dormex available as a generic medicine?

Dormex is a trade name for the active ingredient Zopiclone. Zopiclone is widely available as a generic medicine, meaning it is manufactured and distributed under its chemical name rather than a brand name.


Q: What happens if I drink grapefruit juice while taking Dormex?

Official drug documents warn against combining Zopiclone with strong inhibitors of the CYP3A4 enzyme, as this can lead to increased exposure to the medicine. Grapefruit juice is known to inhibit this enzyme.


Q: Are there different strengths of Dormex tablets available?

Yes, regulatory documents describe Zopiclone as being commonly available in tablet strengths including 7.5 mg and a lower dose of 3.75 mg, which is often used for specific patient populations.


Q: Does Dormex show up on standard drug screening tests?

Zopiclone is a chemically distinct controlled substance, separate from benzodiazepines. It is not generally detected on routine drug screenings, but it can be identified by specific tests designed to look for 'Z-drugs.'


Q: Do people sometimes misuse Dormex?

Official warnings explicitly note that Zopiclone has a potential for abuse, misuse, and addiction, similar to other sedative-hypnotic drugs. Regulatory agencies require a review of the patient's risk for abuse potential before the medicine is prescribed.


Q: Can I take Dormex if I have a history of depression or mental health issues?

Official warnings state that the medicine should be used with caution in patients with a history of depression, as a worsening of depression or suicidal thinking may occur. Caution is also required for those with a history of drug or alcohol abuse.

Advertisements

How should Dormex (Zopiclone) be stored and disposed of?

Official Storage and Disposal Instructions for Zopiclone

Storage and Handling Requirement Official Regulatory Statement
Temperature and Environment Store at room temperature, typically below 30 C (86 F), in a dry place, and protect from light [1.1, 4.1].
Packaging Keep the medicine in its original container or blister pack to maintain stability until the expiry date [1.2, 2.2].
Child Safety It is mandatory to keep this medicine out of the sight and reach of children at all times [1.3, 4.4].
Disposal Do not throw away any medicines via wastewater or household waste [1.3]. Unused product must be disposed of in accordance with local requirements, often by returning it to a pharmacist or using a drug take-back program [4.4].

Regulatory documents mandate that Zopiclone tablets must be protected from heat and light by storing them below the maximum limit of 30 C. The medicine must be kept safely away from children as a primary precaution. For disposal, official instructions prohibit flushing the tablets or placing them in the regular household trash, instead requiring proper disposal through authorized channels.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dormex (Zopiclone) found in:

A-Z Index: